Literature DB >> 25197366

Prognostic significance of mucin expression in urothelial bladder cancer.

Slavica Stojnev1, Ana Ristic-Petrovic1, Ljubinka Jankovic Velickovic1, Miljan Krstic1, Dragan Bogdanovic2, Do Throng Khanh3, Ana Ristic4, Irena Conic5, Vladisav Stefanovic4.   

Abstract

Urothelial bladder cancer (UBC) is a common genitourinary malignancy, accounting for more than 160.000 deaths per year worldwide. Overexpression and aberrant glycosylation of mucins are frequent traits of many human cancers derived from epithelial cells, and are found to have prognostic significance in various carcinomas. The aim of this study was to further elucidate the features and significance of mucin expression in UBC. We investigated the relationship between mucin expression and clinicopathological characteristics in 539 cases of UBC by immunohistochemical analysis of MUC1, MUC2, MUC4, MUC5AC and MUC6 expression profiles. MUC1 stained 61.8% of the tumors and correlated with high tumor grade (P = 0.013). The expression of MUC2 and MUC6 was associated with low tumor grade (P < 0.000 and P < 0.022, respectively), and low pathologic stage (P < 0.001 and P = 0.001, respectively). MUC2 negative tumors were more frequently associated with the finding of carcinoma in situ in tumor surroundings (P = 0.019). UBC with divergent differentiation correlated with MUC1, MUC4 and MUC5AC staining. MUC4 expression was directly linked to cancer specific death (P = 0.027), while MUC2 and MUC6 showed inverse correlation to cancer-specific death (P < 0.001 and P = 0.005, respectively). Kaplan-Meier analyses showed that expression of MUC2 and MUC6 in UBC was significantly associated with better overall survival of the patients (P < 0.001, respectively). In Cox regression model, the absence of MUC6 expression emerged as independent predictor of death outcome. In conclusion, this study identifies MUC2 and MUC6 expression as markers of UBC with less aggressive behavior and useful predictors of better survival.

Entities:  

Keywords:  Urothelial blader cancer; mucins; outcome

Mesh:

Substances:

Year:  2014        PMID: 25197366      PMCID: PMC4152056     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  50 in total

Review 1.  MUC1 mucin in urological malignancy.

Authors:  D P Scholfield; M S Simms; M C Bishop
Journal:  BJU Int       Date:  2003-04       Impact factor: 5.588

2.  Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595.

Authors:  O D Hughes; M C Bishop; A C Perkins; M L Wastie; G Denton; M R Price; M Frier; H Denley; R Rutherford; P A Schubiger
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas.

Authors:  M Saitou; M Goto; M Horinouchi; S Tamada; K Nagata; T Hamada; M Osako; S Takao; S K Batra; T Aikou; K Imai; S Yonezawa
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

4.  Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.

Authors:  Emad A Rakha; Richard W G Boyce; Dalia Abd El-Rehim; Thomas Kurien; Andrew R Green; Emma C Paish; John F R Robertson; Ian O Ellis
Journal:  Mod Pathol       Date:  2005-10       Impact factor: 7.842

5.  MUC1 mucin as a tumour marker in bladder cancer.

Authors:  M S Simms; O D Hughes; M Limb; M R Price; M C Bishop
Journal:  BJU Int       Date:  1999-08       Impact factor: 5.588

6.  Expression of MUC5AC apomucin in transitional cell carcinomas of the urinary bladder and its possible role in the development of mucus-secreting adenocarcinomas.

Authors:  E Kunze; B Francksen; H Schulz
Journal:  Virchows Arch       Date:  2001-11       Impact factor: 4.064

7.  Colorectal cancer in mice genetically deficient in the mucin Muc2.

Authors:  Anna Velcich; WanCai Yang; Joerg Heyer; Alessandra Fragale; Courtney Nicholas; Stephanie Viani; Raju Kucherlapati; Martin Lipkin; Kan Yang; Leonard Augenlicht
Journal:  Science       Date:  2002-03-01       Impact factor: 47.728

8.  Mucin expression by transitional cell carcinomas of the bladder.

Authors:  M D Walsh; B G Hohn; W Thong; P L Devine; R A Gardiner; M L Samaratunga; M A McGuckin
Journal:  Br J Urol       Date:  1994-03

9.  Epithelial membrane antigen as an immunohistochemical marker for transitional cell carcinoma of the urinary bladder.

Authors:  M Takashi; T Murase; T Kinjo; H Mitsuya; H Nagura
Journal:  Urol Int       Date:  1987       Impact factor: 2.089

10.  HMFG-2 as a prognostic indicator in superficial bladder cancer.

Authors:  I G Conn; J Crocker; L A Emtage; D M Wallace
Journal:  J Clin Pathol       Date:  1988-11       Impact factor: 3.411

View more
  13 in total

1.  Invasive urothelial carcinoma with chordoid features of the ureter: a rare entity and review of literature.

Authors:  Jianguo Wei; Zhenying Yue; Dianhang Song; Qiang Wang; Xiaodong Teng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

2.  Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.

Authors:  Tilman Todenhöfer; Jörg Hennenlotter; Nathalie Dorner; Ursula Kühs; Stefan Aufderklamm; Steffen Rausch; Simone Bier; Johannes Mischinger; Doreen Schellbach; Siegfried Hauch; Natalie Feniuk; Jens Bedke; Georgios Gakis; Arnulf Stenzl; Christian Schwentner
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-24       Impact factor: 4.553

3.  Untouchable genes in the human genome: Identifying ideal targets for cancer treatment.

Authors:  Ivan P Gorlov; Olga Y Gorlova; Christopher I Amos
Journal:  Cancer Genet       Date:  2019-01-24

4.  Preclinical evaluation of a hypotonic docetaxel nanosuspension formulation for intravesical treatment of non-muscle-invasive bladder cancer.

Authors:  Trinity J Bivalacqua; Laura M Ensign; Abhijit A Date; Max Kates; Takahiro Yoshida; Taarika Babu; Umara Afzal; Pranjali Kanvinde; Alexander Baras; Nicole Anders; Ping He; Michelle Rudek; Justin Hanes
Journal:  Drug Deliv Transl Res       Date:  2020-11-08       Impact factor: 4.617

5.  Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.

Authors:  Guru P Sonpavde; Benjamin Louis Maughan; Bradley Alexander McGregor; Xiao X Wei; Kerry L Kilbridge; Richard J Lee; Evan Y Yu; Michael Thomas Schweizer; Robert B Montgomery; Heather H Cheng; Andrew Caleb Hsieh; Rohit Jain; Jaspreet S Grewal; Cesar Pico-Navarro; Zarina Gafoor; Teresa Perschy; Petros Grivas
Journal:  Cancer Immunol Immunother       Date:  2022-08-23       Impact factor: 6.630

Review 6.  Ramifications of secreted mucin MUC5AC in malignant journey: a holistic view.

Authors:  Shiv Ram Krishn; Koelina Ganguly; Sukhwinder Kaur; Surinder K Batra
Journal:  Carcinogenesis       Date:  2018-05-03       Impact factor: 4.944

7.  Use of Aleuria alantia Lectin Affinity Chromatography to Enrich Candidate Biomarkers from the Urine of Patients with Bladder Cancer.

Authors:  Sarah R Ambrose; Naheema S Gordon; James C Goldsmith; Wenbin Wei; Maurice P Zeegers; Nicholas D James; Margaret A Knowles; Richard T Bryan; Douglas G Ward
Journal:  Proteomes       Date:  2015-09-03

Review 8.  Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

Authors:  Rita Azevedo; Andreia Peixoto; Cristiana Gaiteiro; Elisabete Fernandes; Manuel Neves; Luís Lima; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  Oncotarget       Date:  2017-07-21

9.  Cancer Chemopreventive Effects of Boswellia sacra Gum Resin Hydrodistillates on Invasive Urothelial Cell Carcinoma: Report of a Case.

Authors:  Ding Xia; Weiwei Lou; Kar-Ming Fung; Cole L Wolley; Mahmoud M Suhail; Hsueh-Kung Lin
Journal:  Integr Cancer Ther       Date:  2016-08-16       Impact factor: 3.279

10.  Loss and gain of N-linked glycosylation sequons due to single-nucleotide variation in cancer.

Authors:  Yu Fan; Yu Hu; Cheng Yan; Radoslav Goldman; Yang Pan; Raja Mazumder; Hayley M Dingerdissen
Journal:  Sci Rep       Date:  2018-03-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.